JP2017504570A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017504570A5 JP2017504570A5 JP2016534640A JP2016534640A JP2017504570A5 JP 2017504570 A5 JP2017504570 A5 JP 2017504570A5 JP 2016534640 A JP2016534640 A JP 2016534640A JP 2016534640 A JP2016534640 A JP 2016534640A JP 2017504570 A5 JP2017504570 A5 JP 2017504570A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- tauopathy
- composition according
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 208000034799 Tauopathies Diseases 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 206010012289 Dementia Diseases 0.000 claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 3
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims 3
- 230000000750 progressive effect Effects 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010059245 Angiopathy Diseases 0.000 claims 2
- 208000017004 dementia pugilistica Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000014644 Brain disease Diseases 0.000 claims 1
- 208000004434 Calcinosis Diseases 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 206010010254 Concussion Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 206010018341 Gliosis Diseases 0.000 claims 1
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 208000010577 Niemann-Pick disease type C Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000007542 Paresis Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000002308 calcification Effects 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 230000009514 concussion Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000007387 gliosis Effects 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 229910052709 silver Inorganic materials 0.000 claims 1
- 239000004332 silver Substances 0.000 claims 1
- 230000002739 subcortical effect Effects 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361909965P | 2013-11-27 | 2013-11-27 | |
| US61/909,965 | 2013-11-27 | ||
| PCT/US2014/067360 WO2015081085A2 (en) | 2013-11-27 | 2014-11-25 | Methods of treating a tauopathy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017504570A JP2017504570A (ja) | 2017-02-09 |
| JP2017504570A5 true JP2017504570A5 (cg-RX-API-DMAC7.html) | 2017-09-28 |
| JP6629201B2 JP6629201B2 (ja) | 2020-01-15 |
Family
ID=52232410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016534640A Expired - Fee Related JP6629201B2 (ja) | 2013-11-27 | 2014-11-25 | タウオパチーの処置方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20160289309A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3074420A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6629201B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN105899230B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016010454A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2931396C (cg-RX-API-DMAC7.html) |
| EA (1) | EA038994B1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX384909B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015081085A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013302540B2 (en) * | 2012-08-16 | 2018-02-15 | Ipierian, Inc. | Methods of treating a tauopathy |
| US12024568B2 (en) | 2012-09-13 | 2024-07-02 | Cornell University | Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| CN105121465B (zh) | 2013-03-13 | 2020-09-08 | 普罗塞纳生物科技公司 | Tau免疫疗法 |
| JP2017512751A (ja) | 2014-02-14 | 2017-05-25 | アイピエリアン，インコーポレイティド | タウペプチド、抗タウ抗体、およびそれらの使用方法 |
| CA3258972A1 (en) | 2015-06-05 | 2025-04-17 | Ac Immune Sa | TAU ANTIBODIES AND METHODS OF USING THEM |
| WO2017100632A1 (en) * | 2015-12-11 | 2017-06-15 | Arizona Board Of Regents On Behalf Of Arizona State University | Human alzheimer's disease and traumatic brain injury associated tau variants as biomarkers and methods of use thereof |
| FI3452507T3 (fi) | 2016-05-02 | 2022-12-15 | Tau-immuunihoito | |
| IL262726B2 (en) | 2016-05-02 | 2024-07-01 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| WO2018106781A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc | Anti-tau antibodies and methods of use |
| JP2020511937A (ja) | 2016-12-07 | 2020-04-23 | ジェネンテック， インコーポレイテッド | 抗ｔａｕ抗体及び使用方法 |
| CN110520440A (zh) | 2017-02-17 | 2019-11-29 | 戴纳立制药公司 | 抗τ抗体及其使用方法 |
| IL270375B2 (en) | 2017-05-02 | 2024-12-01 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| KR20200018502A (ko) * | 2017-06-16 | 2020-02-19 | 브리스톨-마이어스 스큅 컴퍼니 | 타우병증 치료를 위한 조성물 및 방법 |
| US20190135905A1 (en) * | 2017-06-16 | 2019-05-09 | Bristol-Myers Squibb Company | Compositions and methods for treating tauopathies |
| KR20210134943A (ko) | 2019-03-03 | 2021-11-11 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| GB202010652D0 (en) * | 2020-07-10 | 2020-08-26 | Wista Lab Ltd | Anti-tau antibodies |
| CN115607684A (zh) * | 2021-07-15 | 2023-01-17 | 华中科技大学 | 一种内耳药物纳米载体及其应用 |
| TW202334201A (zh) * | 2021-11-03 | 2023-09-01 | 日商衛材R&D企管股份有限公司 | 抗Ｔａｕ抗體之組成物、劑型及方法 |
| WO2025196217A1 (en) * | 2024-03-21 | 2025-09-25 | UCB Biopharma SRL | Treatment of tauopathies with tau-binding antibodies |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4866132A (en) | 1986-04-17 | 1989-09-12 | The Research Foundation Of State University Of New York | Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0318554B2 (en) | 1987-05-21 | 2005-01-12 | Micromet AG | Targeted multifunctional proteins |
| US5256334A (en) | 1988-09-08 | 1993-10-26 | The Research Foundation Of The State University Of New York | Homogeneous radiopaque polymer-organobismuth composites |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
| US5346981A (en) | 1993-01-13 | 1994-09-13 | Miles Inc. | Radiopaque polyurethanes |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
| WO1996019487A1 (en) | 1994-12-22 | 1996-06-27 | Nissan Chemical Industries, Ltd. | Organobismuth derivatives and process for producing the same |
| US5958713A (en) | 1995-01-31 | 1999-09-28 | Novo Nordisk A/S | Method of detecting biologically active substances by using green fluorescent protein |
| US5670477A (en) | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
| US5968738A (en) | 1995-12-06 | 1999-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Two-reporter FACS analysis of mammalian cells using green fluorescent proteins |
| US6020192A (en) | 1996-01-18 | 2000-02-01 | University Of Florida | Humanized green fluorescent protein genes and methods |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| DE69708318T3 (de) | 1996-08-27 | 2006-11-16 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung |
| US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
| TW371617B (en) | 1996-10-09 | 1999-10-11 | Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau | Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV |
| CA2313225A1 (en) | 1997-12-12 | 1999-06-17 | Macromed, Inc. | Heterofunctionalized star-shaped poly(ethylene glycols) for protein modification |
| US5985577A (en) | 1998-10-14 | 1999-11-16 | The Trustees Of Columbia University In The City Of New York | Protein conjugates containing multimers of green fluorescent protein |
| CA2568952C (en) | 2004-06-18 | 2019-05-21 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
| US20090016959A1 (en) | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
| US8741260B2 (en) | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| BRPI0923283A2 (pt) | 2008-12-05 | 2017-06-06 | Angiochem Inc | conjugados terapêuticos de peptídeo e usos dos mesmos |
| JP5917394B2 (ja) * | 2009-06-10 | 2016-05-11 | ニューヨーク・ユニバーシティ | 病理学的タウタンパク質の免疫学的標的化方法 |
| EP2470211B1 (en) * | 2009-08-28 | 2016-01-27 | The Board of Regents of The University of Texas System | Antibodies that bind tau oligomers |
| AU2010315780A1 (en) * | 2009-11-06 | 2012-05-17 | The J. David Gladstone Institutes | Methods and compositions for modulating Tau levels |
| US9304138B2 (en) * | 2010-10-07 | 2016-04-05 | Katholieke Universiteit Leuven | Pharmaceutical composition |
| PT2627672T (pt) * | 2010-10-11 | 2018-11-16 | Univ Zuerich | Anticorpos anti-tau humanos |
| GB201112056D0 (en) * | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| KR20210099167A (ko) * | 2011-09-19 | 2021-08-11 | 악손 뉴로사이언스 에스이 | 알쯔하이머병의 타우 매개된 병리학의 단백질 기재 요법 및 진단 |
| AU2013302540B2 (en) * | 2012-08-16 | 2018-02-15 | Ipierian, Inc. | Methods of treating a tauopathy |
-
2014
- 2014-11-25 WO PCT/US2014/067360 patent/WO2015081085A2/en not_active Ceased
- 2014-11-25 CN CN201480064675.0A patent/CN105899230B/zh not_active Expired - Fee Related
- 2014-11-25 EA EA201690898A patent/EA038994B1/ru unknown
- 2014-11-25 CA CA2931396A patent/CA2931396C/en active Active
- 2014-11-25 EP EP14820979.4A patent/EP3074420A2/en not_active Withdrawn
- 2014-11-25 BR BR112016010454A patent/BR112016010454A2/pt not_active Application Discontinuation
- 2014-11-25 MX MX2016006356A patent/MX384909B/es unknown
- 2014-11-25 US US15/038,711 patent/US20160289309A1/en not_active Abandoned
- 2014-11-25 JP JP2016534640A patent/JP6629201B2/ja not_active Expired - Fee Related
- 2014-11-25 CN CN202010377028.2A patent/CN111569063A/zh active Pending
-
2016
- 2016-05-16 MX MX2021008755A patent/MX2021008755A/es unknown
-
2019
- 2019-04-29 US US16/398,097 patent/US20200102375A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017504570A5 (cg-RX-API-DMAC7.html) | ||
| JP2016503065A5 (cg-RX-API-DMAC7.html) | ||
| AR104875A1 (es) | Anticuerpos anti-tau y métodos de uso | |
| Dunning et al. | Can Parkinson's disease pathology be propagated from one neuron to another? | |
| WO2014058924A3 (en) | Antibodies recognizing alpha-synuclein | |
| MX356800B (es) | Anticuerpo tau humanizado. | |
| IL266911B1 (en) | Anti-tau antibodies and uses thereof in treating tauopathy, retaining or increasing cognitive memory capacity or slowing memory loss | |
| JP2014502141A5 (cg-RX-API-DMAC7.html) | ||
| JP2018519810A5 (cg-RX-API-DMAC7.html) | ||
| JP2018505651A5 (cg-RX-API-DMAC7.html) | ||
| HRP20210522T1 (hr) | Antitijela specifična za hiperfosforilirani tau i načini njihove uporabe | |
| JP2017532288A5 (cg-RX-API-DMAC7.html) | ||
| AU2017291414B2 (en) | Anti-N3pGLu amyloid beta peptide antibodies and uses thereof | |
| NZ739181A (en) | Anti-pyroglutamated amyloid beta humanized antibodies | |
| WO2018175752A8 (en) | Optimized antibody compositions for treatment of ocular disorders | |
| JP2017534638A5 (cg-RX-API-DMAC7.html) | ||
| WO2012045882A3 (en) | Phosphospecific antibodies recognising tau | |
| WO2014204816A3 (en) | Method for assessing protein identity and stability | |
| WO2014160871A8 (en) | Methods and agents for treating alzheimer's disease | |
| MX2021014274A (es) | Moleculas de union anti-tdp-43 y usos de las mismas. | |
| Kroksveen et al. | Cerebrospinal fluid proteomics in multiple sclerosis | |
| JP2018535921A5 (cg-RX-API-DMAC7.html) | ||
| JP2015517502A5 (cg-RX-API-DMAC7.html) | ||
| WO2018089807A3 (en) | Anti-cd46 antibodies and methods of use | |
| HRP20221098T1 (hr) | Tretman kognitivnih i simptoma poremećaja raspoloženja kod neurodegenerativnih i neuropsihijatrijskih poremećaja agonistima gabaa receptora koji sadrže alfa5 |